Pharma Mar S.A./€PHM
1D1W1MYTD1Y5YMAX
Capital at risk
About Pharma Mar S.A.
Pharma Mar S.A. is a biopharmaceutical company based in Madrid, Spain, specializing in the research, development, and commercialization of marine-derived drugs. The company's core focus is on oncology, where it develops and produces antitumor drugs. Its product portfolio includes compounds such as Yondelis, Aplidin, and Zepzelca, each targeting various forms of cancer. Founded in 1986, Pharma Mar is part of the pharmaceutical group Zeltia. The company leverages its unique access to marine biodiversity to create differentiated products, positioning itself distinctively within the pharmaceutical industry. Pharma Mar operates globally, with a significant foothold in both European and international markets.
- Ticker
- €PHM
- Sector
- Health
- Primary listing
- BME
- Employees
- 505
- Headquarters
- Madrid, Spain
- Website
- www.pharmamar.com
Pharma Mar S.A. Metrics
BasicAdvanced
€1.3B
23.67
€3.11
0.42
€1.00
1.36%
Price and volume
Market cap
€1.3B
Beta
0.42
52-week high
€106.00
52-week low
€65.00
Average daily volume
36K
Dividend rate
€1.00
Financial strength
Current ratio
2.855
Quick ratio
2.203
Long term debt to equity
0.134
Total debt to equity
0.183
Interest coverage (TTM)
46.21%
Profitability
EBITDA (TTM)
44.827
Gross margin (TTM)
93.38%
Net profit margin (TTM)
25.67%
Operating margin (TTM)
17.78%
Effective tax rate (TTM)
-37.54%
Revenue per employee (TTM)
€430,000
Management effectiveness
Return on assets (TTM)
6.55%
Return on equity (TTM)
24.82%
Valuation
Price to earnings (TTM)
23.666
Price to revenue (TTM)
6.074
Price to book
5.09
Price to tangible book (TTM)
5.17
Price to free cash flow (TTM)
25.989
Free cash flow yield (TTM)
3.85%
Free cash flow per share (TTM)
2.834
Dividend yield (TTM)
1.36%
Growth
Revenue change (TTM)
15.52%
Earnings per share change (TTM)
29.14%
3-year revenue growth (CAGR)
7.68%
10-year revenue growth (CAGR)
1.50%
3-year earnings per share growth (CAGR)
39.02%
10-year earnings per share growth (CAGR)
20.50%
3-year dividend per share growth (CAGR)
15.44%
Bulls say / Bears say
On June 1, 2026 the European Commission granted centralised marketing authorisation for Zepzelca® in combination with atezolizumab as first-line maintenance therapy for extensive-stage small cell lung cancer across the EU (Reuters (tradingview.com)).
Health authorities in Canada, Qatar and South Korea approved PharmaMar’s Zepzelca® plus Tecentriq® combination for first-line maintenance in extensive-stage small cell lung cancer on August 3, 2026, extending its approved territory to 18 countries (Reuters (stockopedia.com)).
PharmaMar launched a share buyback programme on June 30, 2026 to repurchase up to 90 000 shares (0.5% of capital) for a maximum of €8 million through February 28, 2027, signalling management’s confidence in the stock’s valuation (Reuters (stockopedia.com)).
Top-line results from the Phase III LAGOON trial announced June 12, 2026 showed Zepzelca® (lurbinectedin) failed to meet its primary overall survival endpoint in second-line metastatic small cell lung cancer, raising doubts over its expanded indications (Reuters (es.tradingview.com)).
PharmaMar’s EBITDA plunged to €3.6 million in H1 2026 from €25.1 million in H1 2025, as prior-year grants and one-off licensing income dissipated, highlighting weakening operating profitability (PharmaMar press (pharmamar.com)).
Net profit collapsed to just €0.6 million in the first half of 2026, down from €19.4 million a year earlier, driven by the absence of non-recurring revenue such as Merck upfront payments and grants in the current period (PharmaMar press (pharmamar.com)).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
Upcoming events
No upcoming events
Funds containing Pharma Mar S.A.
AllEURUSDGBP
Fund name | Fund size | €PHM weighting |
|---|---|---|
Xtrackers Spain€XESD | €269M | 0.12% |
iShares Healthcare Innovation$HEAL | $1.4B | 0.11% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.11% |
iShares Healthcare Innovation£DRDR | £1B | 0.11% |
iShares Ageing Population€AGED | €822M | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.